FDA Approves Emergency Use of CDC Test for Zika Virus

Share this content:
FDA Approves Emergency Use of CDC Test for Zika Virus
FDA Approves Emergency Use of CDC Test for Zika Virus

HealthDay News — The US Food and Drug Administration has issued an Emergency Use Authorization (EUA) for a diagnostic tool for Zika virus that will be distributed to qualified laboratories.

The test is called the CDC Zika immunoglobulin M (IgM) Antibody Capture Enzyme-Linked Immunosorbent Assay (Zika MAC-ELISA), and is intended for use on blood samples from people with a history of symptoms associated with Zika and/or people who have recently traveled to an affected area. The IgM antibodies in response to infection appear in the blood beginning 4 to 5 days after the start of illness and last for about 12 weeks.

When positive or inconclusive results occur, additional testing with a plaque reduction neutralization test is recommended to confirm the presence of antibodies to Zika virus. This additional testing will be performed by the CDC or a CDC-authorized laboratory.

"The CDC will begin distributing the test during the next two weeks to qualified laboratories in the Laboratory Response Network, an integrated network of domestic and international laboratories that can respond to public health emergencies," according to the media statement. "The test will not be available in US hospitals or other primary care settings."

To read the full CDC statement, go here.

You must be a registered member of Neurology Advisor to post a comment.

Next Article in General Neurology

Sign Up for Free e-newsletters

CME Focus